Skip to main content
    A

    Abivax SA American Depositary Shares (ABVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $85.73
    +1.55 (+1.85%)

    Market Cap: $7.37B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(6/13)
    Avg Surprise
    -13.98%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.86
    Range$-1.11 - $-0.59
    4 analysts
    EPS Revisions
    1
    0
    7d
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.67-27.4%
    60d ago$-0.67-27.4%
    30d ago$-0.76-12.3%
    7d ago$-0.86+0.3%
    Current$-0.86
    Revenue Consensus
    $676440
    Range$0 - $1M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.65
    Range$-2.14 - $-1.29
    7 analysts
    Revenue Consensus
    $2M
    Range$-1834410 - $6M
    14 analysts
    Last 12 of 26 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-1.65$-2.14 - $-1.29--7--
    Sep 26EST
    		-$-0.86$-1.11 - $-0.59--4
    0
    3
    30d
    		-
    Jun 26
    Reported Sep 21
    		$-1.71$-1.08$-1.42 - $-0.56-58.33%Miss4
    1
    0
    30d
    		-92.1%
    Mar 26
    Reported May 22
    		$-0.71$-0.81$-0.84 - $-0.78+12.35%Beat2
    0
    1
    30d
    		+25.3%
    Dec 25
    Reported Mar 23
    		$-1.18$-1.04$-1.04 - $-1.04-13.46%Miss1
    1
    0
    30d
    		-44.9%
    Sep 25
    Reported Dec 15
    		$-2.47$-0.79$-0.79 - $-0.79-212.66%Miss1
    1
    0
    30d
    		-243.1%
    Jun 25
    Reported Sep 8
    		$-0.89$-0.95$-0.95 - $-0.95+6.32%Beat1
    0
    1
    30d
    		+11.9%
    Mar 25
    Reported Jun 2
    		$-0.95$-0.76$-0.76 - $-0.76-25.00%Miss0
    No revisions (30d)
    		-20.2%
    Dec 24
    Reported Mar 24
    		$-0.81$-1.29-+36.88%Beat5
    No revisions (30d)
    		-
    Sep 24
    Reported Nov 7
    		$-0.72$-0.79-+8.86%Beat---12.5%
    Jun 24
    Reported Sep 9
    		$-1.01$-0.97--4.12%Miss---40.3%
    Mar 24
    Reported Apr 2
    		$-0.79$-0.60--31.72%Miss--+59.4%
    Dec 23
    Reported Feb 6
    		$0.00N/A-+100.00%Beat0
    No revisions (30d)
    		+100.0%
    Sep 23
    Reported Nov 29
    		$-0.64$-0.64$-0.64 - $-0.64+0.00%Beat0
    No revisions (30d)
    		+61.9%

    Key Metrics

    Valuation
    P/E Ratio-14.12EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-8618.00%
    ROE-252.30%ROIC-159.61%
    Financial Health
    Debt/Equity0.00xInterest Coverage-25.13x
    Current Ratio5.97xQuick Ratio5.97x
    Trading Statistics
    Beta-0.34Avg Volume967.55K
    52-Week High$148.8352-Week Low$69.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$87.20
    SMA 20$88.27
    SMA 50$97.20
    SMA 200$113.28
    EMA 10$87.27
    EMA 20$88.98
    EMA 50$96.32
    EMA 200$104.51

    MACD

    Line: -2.83Signal: -3.24Hist: 0.41

    ADX

    ADX: 24.9+DI: 18.5-DI: 28.9

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down84.0
    PSAR$91.32

    Bollinger Bands

    Upper Band$93.30
    Lower Band$83.24
    %B Position1140%(Upper)
    Band Width0.25

    RSI (14-Day)

    Neutral
    42.1

    Momentum Oscillators

    Stoch %K22.7
    Stoch %D28.5
    Williams %R-83.0
    ROC (10d)-2.6%
    Momentum-2.28
    CCI (20d)-113.3
    MFI (14d)51.8

    Volatility Measures

    ATR (14d)$4.22(4.9%)
    StdDev (20d)2.52
    Hist Vol50.5%(High)

    Volume Flow

    VWAP$85.39
    OBV31.4M
    AD Line-20.2M
    CMF (20d)-0.071

    Volume Metrics

    Avg Vol (20d)914.5K
    Vol Ratio0.9x
    VWMA (20d)$88.52

    Pivot Points

    R3$96.62
    R2$93.97
    R1$89.07
    Pivot Point$86.42
    S1$81.52
    S2$78.87
    S3$73.97

    Advanced Oscillators

    TSI-17.15
    Ultimate Osc38.4
    KST-90.21

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Jun 2023
    Total Revenue$0$0$-2,017,000$0$2.02M$0$7.40M$0$3.39M$0$2.33M$2.25M
    Cost of RevenueN/AN/A$1.03MN/AN/AN/AN/AN/AN/AN/A$378,000$329,000
    Gross ProfitN/AN/A$-3,046,690N/A$2.02MN/A$7.40MN/A$3.39MN/A$2.33M$2.25M
    Operating Expenses$84.11M$56.23M$199.56M$80.71M$46.50M$47.20M$47.20M$50.19M$35.33M$44.67M$92.08M$39.21M
    R&D$58.34M$49.54M$44.40M$55.42M$38.65M$39.30M$39.30M$43.29M$28.91M$35.74M$70.55M$32.62M
    SG&A$26.87M$8.03M$27.68M$27.34M$8.91M$8.89M$8.72M$8.23M$11.70M$10.11M$15.63M$6.58M
    Operating Income$-84,111,000$-56,229,000$-199,560,000$-80,712,000$-46,496,000$-47,200,000$-47,200,000$-50,189,000$-35,326,000$-44,671,000$-92,462,000$-39,535,000
    Interest Income$1.28M$769,000$807,000$3.53M$319,000$1.09M$1.64M$2.15M$2.45M$2.75M$0$0
    Interest Expense$730,000$2.54M$15.27M$4.21M$3.52M$4.54M$4.54M$4.74M$3.83M$2.42M$5.70M$14.70M
    Income Before Tax$-123,508,000$-48,240,000$-281,840,000$-153,358,000$-48,414,000$-52,370,000$-52,370,000$-55,227,000$-38,770,000$-42,867,000$-98,045,000$-54,188,000
    Income Tax Expense$-6,076,000$0$5.85M$0$0$0$0$0$0$0$-2,258,000$-2,235,000
    Net Income$-117,433,000$-48,468,000$-287,688,000$-153,358,000$-48,414,000$-52,370,000$-52,370,000$-55,227,000$-38,771,000$-42,867,000$-95,787,000$-51,953,000
    EBITDA$-122,404,000$-45,333,000$-256,512,000$-148,873,000$-44,642,000N/A$-47,562,000N/A$-34,577,000N/A$-92,084,000$-39,206,000
    EBIT$-122,778,000$-45,700,000$-256,879,000$-149,145,000$-44,893,000N/A$-47,835,000N/A$-34,942,000N/A$-92,462,000$-39,535,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ABVX

    News

    Abivax among the best performers in the SBF 120, after a 24% drop over the quarter

    Abivax, a Paris-based biotech, is experiencing a significant rebound, with its shares gaining 3.96% to €82.70, placing it among the top performers in the SBF 120. This recovery follows a challenging quarter where...

    Idéal Investisseur•11/5/26•Neutral

    Abivax among the best performers of the SBF 120 despite a -24.5% decline over the quarter

    Abivax, a Parisian biotech specializing in inflammatory diseases, saw its stock rise sharply, positioning it among the SBF 120 leaders despite a 24.55% decline over the last three months. The stock's rebound allowed it...

    Idéal Investisseur•11/3/26•Neutral

    Abivax SA American Depositary Shares (ABVX) Stock Price, Chart & Analysis

    This article provides a detailed analysis of Abivax SA American Depositary Shares (ABVX) stock, covering its current price, market capitalization, key financial figures...

    www.debelegger.nl•11/3/26•Somewhat-Bearish

    Abivax shares at the bottom of the SBF 120, down 27% over the quarter

    Abivax shares are significantly down, trading 1.9% lower intraday at €77.55 while the SBF 120 is up. The biotech stock has dropped 27.05% over the quarter and is currently below its main moving averages...

    Idéal Investisseur•11/2/26•Bearish

    ABIVAX Société Anonyme (0RA9.L) Seasonal returns chart

    The article states that seasonality data is currently unavailable for ABIVAX Société Anonyme (0RA9.L). It provides current stock information, showing the company's stock at 76.65 EUR...

    Yahoo Finance UK•10/31/26•Neutral

    ABVX Valuation and Fair Value

    P/E
    -14.1x
    P/B
    16.3x
    See GNG's fair value

    ABVX Profitability: Margins, ROIC and FCF

    Operating margin
    -8618.0%
    Net margin
    0.0%
    ROIC
    -159.6%
    ROE
    -252.3%

    ABVX Competitors

    CompanyTicker
    10X Genomics IncTXG
    Caris Life Sciences, Inc. Common StockCAI
    Rhythm Pharmaceuticals IncRYTM
    Praxis Precision Medicines IncPRAX
    Cytokinetics IncCYTK
    Axsome Therapeutics IncAXSM
    PACS Group, Inc.PACS
    Kiniksa Pharmaceuticals LtdKNSA

    Sector: Healthcare

    ABVX Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    4
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ABVX Bull Case vs Bear Case

    Bull case

    • 100.0% of ABVX's analyst ratings are Buy or Strong Buy.

    Bear case

    • ABVX's quarterly revenue changed -6.8% year over year.

    ABVX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -30.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.86
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    ABVX Earnings Date

    ABVX reports Dec 21, 2026. The date is confirmed.

    ABVX ETF Holders

    GNG tracks 2 ETFs that hold ABVX. The largest weights:

    1. iShares Biotechnology ETF (IBB), 0.44% of the fund
    2. Vanguard European Stock Index Fund ETF Shares (VGK), <0.01% of the fund
    Open the ETF Stock Exposure tool for ABVX

    Frequently Asked Questions About ABVX

    When does ABVX report earnings?

    Abivax SA American Depositary Shares (ABVX) is confirmed to report earnings on Dec 21, 2026.

    Does ABVX pay dividends?

    Abivax SA American Depositary Shares (ABVX) does not currently pay a regular dividend.

    What is ABVX's market cap?

    Abivax SA American Depositary Shares (ABVX) has a market capitalization of $7.37B with a current stock price of $85.73.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In